Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Passage Bio ( (PASG) ) has issued an announcement.
On April 28, 2026, Passage Bio, Inc., as part of its ongoing review of strategic alternatives to maximize shareholder value, announced a sweeping restructuring plan that will reduce its workforce by approximately 75% to lower operating expenses. The restructuring is expected to be substantially completed during the second and third quarters of 2026, with total severance and exit costs estimated at about $3.3 million, although the company noted that actual costs could differ and additional expenses may arise from the plan and the broader strategic review.
Impacted employees are eligible for severance benefits contingent on signing and not revoking a severance agreement that includes a general release of claims against the company. The majority of the restructuring-related charges are expected to be recorded in the second quarter of 2026, marking a significant contraction in Passage Bio’s operations that could materially reshape its cost structure and operational footprint as it evaluates its future direction.
The most recent analyst rating on (PASG) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.
Spark’s Take on PASG Stock
According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.
The score is held down primarily by weak financial fundamentals for a pre-revenue biotech (ongoing losses, negative free cash flow, and sharply reduced equity with higher leverage). Technicals also point to a weak trend with the stock below major moving averages. Offsetting these risks, corporate updates around clinical progress and stated runway provide some support, but not enough to outweigh the financial and trend-related concerns.
To see Spark’s full report on PASG stock, click here.
More about Passage Bio
Passage Bio, Inc. is a biotechnology company focused on developing genetic medicines, positioning itself within the biopharmaceutical industry with an emphasis on innovative therapies. The company targets severe diseases with significant unmet medical need, aiming to advance treatments that can improve outcomes for patients and create value for shareholders.
Average Trading Volume: 69,219
Technical Sentiment Signal: Strong Sell
Current Market Cap: $18.73M
Learn more about PASG stock on TipRanks’ Stock Analysis page.